Artivion (AORT)

• Market cap: $962M
• 1 day: -1.74%
• 5 days: -4.41%
• 1 month: -7.78%
• 3 months: -28.68%
• 6 months: -15.43%
• Year to date: -19.76%
• 1 year: 10.88%
• 5 years: 14.48%
• 10 years: 121.10%
• Sector: Healthcare
• Industry: Medical Devices

About: Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.

Employees: 1,600

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1,252% more call options, than puts

Call options by funds: $892K | Put options by funds: $66K

13% more capital invested

Capital invested by funds: $961M [Q3] → $1.09B (+$129M) [Q4]

5.2% more ownership

Funds ownership: 86.19% [Q3] → 91.4% (+5.2%) [Q4]

5% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 22

1% more funds holding

Funds holding: 172 [Q3] → 173 (+1) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 57

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $30 33% upside
• Avg. target: $32 41% upside
• High target: $33 46% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Citizens Capital Markets Daniel Stauder 9% 1-year accuracy 1 / 11 met price target	46% upside $33	Market Outperform Reiterated	25 Feb 2025
Stifel Rick Wise 24% 1-year accuracy 8 / 34 met price target	33% upside $30	Buy Maintained	25 Feb 2025
Needham Mike Matson 22% 1-year accuracy 27 / 121 met price target	42% upside $32	Buy Maintained	25 Feb 2025